From this presentation attendees will:
-Achieve greater understanding of the nature and properties of biofilms;
-Understand the contribution of pathogenic biofilm to chronic and recurrent infections;
-Learn to disrupt pathogenic biofilm using antibiofilm enzymes.
Stephen F. Olmstead, MD, is Chief Science Officer at ProThera, Inc. where he directs clinical trials of ProThera® and Klaire Labs™ nutraceutical products. He received his MD from the University of New Mexico in 1979 and completed his Internal Medicine residency at Harvard Medical School, Massachusetts General Hospital in 1982 and fellowship in Cardiovascular Diseases at the University of Washington in 1987. His current research focuses on the use of enzymes and chelating agents to disrupt pathogenic GI biofilm and pre- and probiotics to restore gut microbial balance.
Join us early at 3:50 PM PST for the Announcements Segment and a brief interview with Dr. Olmsted.
RSVP Here: https://attendee.gotowebinar.com/register/7382341338263497985
Stephen Olmstead, MD